Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

H. Lundbeck A/S. (6/6/17). "Press Release: Lundbeck Obtains Rights to Breakthrough Research in Alzheimer's Disease". Valby.

Organisations Organisation H. Lundbeck A/S
  Group Lundbeck (Group)
  Organisation 2 ImmunoBrain Checkpoint Ltd. (IBC)
Products Product Alzheimer drug
  Product 2 drug discovery
Persons Person Tolstrup, Jacob (Lundbeck 201203– VP Business Development before 10 years at Lundbeck)
  Person 2 Kronborg, Mads (Lundbeck 201309 Media Relations Manager)

Novel approach can potentially lead to future treatments that may both treat symptoms and stop the progression of Alzheimer's disease.

H. Lundbeck A/S (Lundbeck) has entered into an agreement with biotech company ImmunoBrain Checkpoint, Inc. (IBC) for the rights to IBC's groundbreaking research in the treatment of Alzheimer's disease. The research focuses on modifying antibodies currently used in cancer treatment for use in treating the debilitating brain disease which 48 million patients are estimated to suffer from[i]. A number expected to rapidly increase in the future.

"IBC has a unique and innovative approach to this highly complex disease and the data generated until now are highly promising. We are delighted to take part in this exciting work as part of our strategy of in-licensing research projects to supplement our own research activities", says Jacob Tolstrup, Executive Vice President for Corporate Functions, including Business Development.

The agreement stipulates that Lundbeck will fund and partake in the continued research aimed at identifying drug candidates for clinical testing. Further, Lundbeck gets minority ownership in IBC and the exclusive option to potentially take over all rights and activities at a later time.

IBC's research is still at an early stage and it will take years before the treatment concept may be ready for testing in humans.


Mads Kronborg
Senior Director, Corporate Communication
Phone: +45 36 43 40 00

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders — we call this Progress in Mind.


Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.3 billion).

For additional information, we encourage you to visit our corporate site and connect with us on Twitter at @Lundbeck.

[i] (December 2016)

Record changed: 2017-09-26


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Lundbeck (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 650x65px

» top